|
|
本帖最后由 马陆 于 2025-7-26 22:03 编辑
1. Qurashi M, Vithayathil M, and Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. (2025) 51:107064. doi: 10.1016/j.ejso.2023.1070642. Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. (2021) 7:65. doi: 10.1038/s41572-021-00300-2
3. Valle JW, Kelley RK, Nervi B, Oh DY, and Zhu AX. Biliary tract cancer. LANCET. (2021) 397:428–44. doi: 10.1016/S0140-6736(21)00153-7
4. Kidanemariam S, Gu J, Yoon JH, Challapalli JV, Fruh V, and Sax AJ. Cholangiocarcinoma: epidemiology and imaging-based review. R I Med J (2013). (2024) 107:43–8.
5. Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, et al. Invernizzi P et al: Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. (2022) 27:100737. doi: 10.1016/j.aohep.2022.100737
文章中的格式是In response to this challenge, innovative approaches have been proposed, such as employing the ratio of CA19–9 to bilirubin to mitigate the influence of inflammation and biliary obstruction on biomarker interpretation (38–40).
|
|
发表于 2025-7-26 22:01:34
发表于 2025-7-30 00:21:22